Lung Function Measurements at the Clinic
The FEVi and FVC after all treatments were significantly higher than the values measured at the start of the study (Table 3), but there was no significant difference between the treatments. The measurements were done 2 to 8 hours after the morning dose, but were performed at the same time of the day for each patient. flovent inhaler
Additional Use of fa-Agonist
There was no significant difference between the treatments in the use of additional puffs of p2-agonists; mean number of additional puffs per day were 4.3, 4.6, and 4.4 during “PEIT “terbutaline,” and “terbu-taline-PEp* respectively.
This study compared the effect on daily peak expiratory flow and symptoms of PEP, inhaled terbu-taline, and combined terbutaline-PEP inhalation in home treatment of bronchial asthma. The bronchodi-lation after inhaled terbutaline was enhanced by the combination with PEP, shown by the immediate increases in PEF. The symptom scores showed only small differences; however, the scales to differentiate symptom severity were not detailed. No side effects were reported.
It was not possible to make a double-blind design, because the expiratory pressure can be felt, and treatment with placebo without PEP was not included due to the severity of the disease; but with the three treatments, we endeavored to make the nearest possible approach to a double-blind design.
Table 3—Forced Expiratory Volume in First Second (FEVJ and Forced Expiratory Vital Capacity (FVC) Measured at the Clinic before and after Two weeks of Treatment with Positive Expiratory Pressure (PEP), Terbutaline Inhalation (Terb\ and PEP Combined with Terbutaline Inhalations (Terb-PEP).
|Treatment||FEV„ L||FVCY L|
|Baseline||1.63 (1.09-2.52)||2.70 (2.02-3.58)|
|PEP||X.82 (1.19-2.62)||2.88 (2.10-3.65)|
|Terb||1.99 (1.05-2.59)||2.96 (1.81-3.47)|
|Terb-PEP||2.00 (1.28-2.72)||3.10 (2.32-3.88)|